Source: globenewswire_biotech
Source ID: globenewswire_biotech:https://www.globenewswire.com/news-release/2026/10/28/3390040/0/en/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-trial-results-for-lorundrostat-in-kidney-international.html:MLYS
URL: https://www.globenewswire.com/news-release/2026/10/28/3390040/0/en/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-trial-results-for-lorundrostat-in-kidney-international.html
Symbol: (MLYS)
Published: 2026-10-28 07:05:00 EDT
Time precision: minute
Title: Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -